Your SlideShare is downloading. ×
0
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Prolactinoma
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Prolactinoma

2,825

Published on

Published in: Health & Medicine
1 Comment
5 Likes
Statistics
Notes
No Downloads
Views
Total Views
2,825
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
89
Comments
1
Likes
5
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Prolactinom Dr. Mohmmed AL jaberi 09/05/2012
  • 2. Outlines Intorductions Epidemiology Clinical Manifestations Diagnosis Treatment Follow Up Summary
  • 3. Introductions• Prolactin (PRL) is a polypeptide protein hormone secreted by the lactotroph cells in the anterior pituitary gland .• Suppressed by hypothalamic dopamine to act on Lactotroph D2 receptors .• Prolactin (PRL) is the hormone act as stimulation & maintenance of milk production in the breast .
  • 4. Prolactin Regulation
  • 5. Epidemiology• Most common functional pituitary adenomas .• Prolactinoma account for 40 % of pituitary tumor .• Microprolactinomas are more frequent in women .• Macroprolactinomas are more frequent in men .• Gender : femal more than male 10 :1• Age : 20-50 years .• Some growth hormone producing tumors also cosecrete PRL
  • 6. Clinical Manifestations• Hormonal Effect : • Women : infertility, oligomenorrhea, amenorrhea or rarely galactorrhea .• Men : decreased libido, impotence, infertility, gynecomastia, or rarely galactorrhea .
  • 7. Clinical Manifestations• Mss Effect : headache ,CSF rhinorrhea , compression of optic chiasma & cranial nerve .
  • 8. Diagnosis• Clinically : by excluded 2o cause of HPRL .(A) Physiological ( pregnancy ,stress ,nipple suckle )(B) Hypothalamic - pituitary disease ( tumor, trauma, infiltrative )(C) Others : hypothyroidism, chest injury, CRF .(D) Drugs .
  • 9. Drugs Antihypertensive agents Antipsychotics agentMethyldopa (Aldomet) Phenothiazine drugsReserpine (Hydromox, Serpasil, Haloperidol (Haldol)others) Risperidone (Risperdal)Verapamil (Calan, Isoptin) Gastrointestinal drugs Cimetidine (Antiacid) Metoclopramide (Antaemetic) Antidepressant agents Opiates Clomipramine (Anafranil) Codeine Desipramine (Norpramin) Morphine
  • 10. • Biochemical : by serum PRL concentration* Normal range for serum prolactin is 5 - 20 ng/mL .* Serum prolactin values above 200 ng/mL usually indicate the presence of a lactotroph adenoma• Hook effect : can be observed in macroprolactinomas. the extremely high PRL levels cause antibody saturation , the resulting in an artifactually low reported value .This can be eliminated by dilution of serum samples.* Other s: FSH ,LH ,GH ,TSH, FT4 , RFT, LFT .
  • 11. Ranges of serum prolactin concentrations in several causes of hyperprolactinemia
  • 12. • Imaging : MRI Of Head* Should be performed in a patient with any degree of hyperprolactinemia to look for a mass lesion in the hypothalamic-pituitary region .
  • 13. Treatment* The indications for treatment :1) Neurologic symptoms .2) Hypogonadism or other symptoms .* The corner stone treatment of prolactinomas are medical treatment .
  • 14. 1) DOPAMINE AGONISTS Dopamine agonists decrease prolactin secretion and reduce the size of the lactotroph adenoma in more than 90 % of patients. Decrease symptoms within days . Decrease in serum prolactin within 2-3 weeks . Decrease in size within 6 weeks ... ( 6 month ) .
  • 15. 1) DOPAMINE AGONISTS Bromocriptine : It was given at least twice a day . 1.25 -2.5 mg PO at bedtime or with dinner. ( max. 15 mg / d ) Cabergoline : administered once or twice a week . 0.25 mg twice /wk or 0.5 mg once/wk . Adverse effects : Common Less common Nausea Nasal stuffiness, Postural Depression, Raynaud hypotension phenomenon, Constipation Mental fogginess valvular heart disease
  • 16. 1) DOPAMINE AGONISTSIn a multicenter, randomized, 24-week trial conducted in459 hyperprolactinemic women * Cabergoline Bromocriptin Normal PRL 83% 59% Pregnancies 72% 52% (Ovulation) Stopped S/E 3% 12% * Webster J, Piscitelli G, Polli A, et al.A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative Study Group.N Engl J Med 1994;331(14):904–9 .
  • 17. Dopamine agonist drugs lower serum prolactin concentrations in prolactinoma
  • 18. 2)TRANSSPHENOIDAL SURGERY* The indications for surgery :1) Patients who do not respond to medical treatment or those who show progression after an initial response to medical treatment .2) Women who have a microadenoma, desire pregnancy, and cannot tolerate medical treatment.
  • 19. 3) RADIATION THERAPY* The indications for radiation : radiation is primarily used to prevent regrowth of residual tumor in a patient with a very large macroadenoma after transsphenoidal debulking .
  • 20. 4) ORAL CONTRACEPTIVE* The indications for Estrogen- progestin : can be considered as therapy in women with symptomatic microprolactinomas IF : women cannot tolerate or do not respond to dopamine agonists or do not want to become pregnant.
  • 21. Follow Up* After one month of therapy, the patient should be evaluated for side effects and serum prolactin should be measured , So : If the serum PRL is normal and no S/E So, (continued). If the serum PRL not decreased to normal but no S/E , the dose should be increased gradually to as much as 1.5 mg of Cabergoline 2 or 3 times / week or 5 mg of Bromocriptine 2 times / day. Whatever dose results in a normal serum prolactin value should be continued If the prolactin has been normal for two or more years and no adenoma is seen on MRI So, discontinuation of the drug .
  • 22. SUMMRAY• Most common functional pituitary adenomas• Most frequently in women with gender ratio of 10:1.• Diagnosis clinically, biochemically & imaging .• Macroadenoma with low PRL levels ( hook effect) .• MRI should be performed to confirm the diagnosis .• Medical therapy with DA is the treatment of choice .• Cabergoline is the first-line treatment• Transsphenoidal surgery remains an option when medical therapy is ineffective .• Radiotherapy represents the last option .
  • 23. Thank You

×